Evaluation of candidemia and antifungal consumption in a large tertiary care Italian hospital over a 12-year period
- 201 Downloads
An early adequate antifungal therapy based on the knowledge of local epidemiology can reduce the candidemia-attributable mortality and the length of hospitalization. We performed a retrospective study to analyze the epidemiology of candidemia and the antifungal consumption in our hospital.
We analyzed Candida spp. isolated from the blood, and their susceptibility profile from 2005 to 2016 in Careggi University Hospital, Florence, Italy. We also performed a stratified analysis by clinical setting where Candida spp. were isolated (Medical Wards, Surgery, Intensive Care Unit-ICU). Then, we retrospectively reviewed the annual consumption of antifungal agents and calculated the defined daily dosing for 10,000 hospital days.
The rate of candidemia was higher in ICU than other settings and Candida albicans was the first cause of candidemia (61.2%). After adjustment for hospital days, the rate of C. albicans showed a statistically significant parabolic trend (p < 0.001), with a peak of incidence in 2010. After 2010, we observed a reduction of candidemia due to both C. albicans and non-albicans species. Between 2005 and 2015, we reported an increasing increased use of echinocandins. As far as resistance profile is concerned, only one Candida glabrata isolate was resistant to caspofungin (1.9%) and 30% of C. glabrata were resistant to fluconazole.
Our data describe C. albicans as the first cause of candidemia in all the studied settings and the low rate of echinocandin resistance, despite their increased use over the study period. ICU was confirmed as the setting with the highest incidence of candidemia.
KeywordsCandidemia Echinocandin Antifungal consumption Candida albicans Antifungal susceptibility
In 2015, JM received a research fellowship from Società Italiana Malattie Infettive e Tropicali (SIMIT).
Compliance with ethical standards
Conflict of interest
JM received grant support from Gilead, MSD Italy, outside the submitted work. GMR received grants, personal fees and other from Pfizer, MSD Italy, outside the submitted work. AB received grants and personal fees from MSD Italy and Pfizer, grants from Gilead and Astellas, outside the submitted work. LT, EM, ER, RF, FB, GC, AF, PP and LB have no conflict of interest to declare.
- 1.European Centre for Disease Prevention and Control. Annual epidemiological report 2014. Antimicrobial resistance and healthcare-associated infections. Stockholm: ECDC; 2015.Google Scholar
- 2.Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol. 2004;42:1519–27.CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clin Infect Dis. 2012;55:1352–61.CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Klingspor L, Tortorano AM, Peman J, Willinger B, Hamal P, Sendid B, et al. Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006–2008). Clin Microbiol Infect. 2015;21:87.CrossRefPubMedGoogle Scholar
- 18.Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56:1724–32.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Clinical and Laboratory Standards Institute, Wayne, PA. CLSI 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. CLSI document M27-S4Google Scholar
- 29.De Francesco MA, Piccinelli G, Gelmi M, Gargiulo F, Ravizzola G, Pinsi G, et al. Invasive candidiasis in Brescia, Italy: analysis of species distribution and antifungal susceptibilities during 7 years. Mycopathologia. 2017. https://doi.org/10.1007/s11046-017-0155-3 (Epub ahead of print).PubMedGoogle Scholar